Business
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022. Mini-Oral Presentations: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)Presentation #: MO209Session Title: GlomerulonephritisDate & Time: Thursday, May 19, 2022, 8:00-12:45 CEST Baseline Characteristics of Patients Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (DUPLEX) Presentation #: MO254Session Title: GlomerulonephritisDate & Time: Thursday, May 19, 2022, 8:00-12:45 CEST Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS)Presentation #: MO255Session Title: GlomerulonephritisDate & Time: Thursday, May 19, 2022, 8:00-12:45 CEST Sparsentan, the Dual Endothelin Angiotensin Receptor Antagonist (DEARA), Attenuates Albuminuria and Protects from the Development of Renal Injury to a Greater Extent Than Losartan in the gddY Mouse Model of IgA Nephropathy: A 16-Week StudyPresentation #: MO261Session Title: Quick Fire Session 1Date & Time: Friday, May 20, 2022, 16:30-18:00 CEST About the PROTECT Study The ongoing PROTECT Study is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400mg of sparsentan, compared to 300mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite available ACE or ARB therapy. In August 2021, the Company announced the PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance. After 36 weeks of treatment, patients rec...